On December 6, 2024, KisoJi, a biotechnology company that is focused on treating diseases through its advanced platform, announced it raised $57 million of Series B financing.

This round was co-led by Investissement Québec and Lumira Ventures. The round also saw participation from Fonds de solidarité FTQ, adMare BioInnovations and Remiges Ventures.

The company plans on utilizing the funding towards advancing antibody cancer treatment and research purposes leveraging artificial intelligence.

Osler, Hoskin & Harcourt LLP advised KisoJi with a team consisting of Nathalie Beauregard, Sarah Miles and Michèle Orr Gaucher (Emerging and High Growth Companies).